LENZ Therapeutics (LENZ) Corporate presentation summary

Product and clinical profile

• VIZZ is an FDA-approved aceclidine 1.44% eye drop for presbyopia; launched in October 2025 and described as the only pupil-selective miotic.

• In CLARITY 2, 91% of patients improved near vision by ≥2 lines within 30 minutes, 71% by ≥3 lines at 3 hours, and 69% by ≥2 lines at 10 hours after a once-daily dose.

• ~7 in 10 patients achieved functional 20/40 near vision at 10 hours; 99% achieved the target pupil size of <2 mm.

• No serious treatment-related adverse events; <4% discontinued due to treatment-related adverse events, and the majority of adverse reactions were mild, transient, and self-resolving.

Launch and commercialization

• Q3 2026 prescriptions grew 50% QoQ, with 110K total TRx since launch; VIZZ was positioned as the leading prescription eye drop in the emerging US presbyopia market.

• More than 15,000 ECPs had prescribed VIZZ, with over 75% prescribing more than once; aided awareness exceeded 90% and unaided awareness exceeded 80% as of July 2026.

• Commercial strategy combines ECP education, 2026 direct-to-consumer advertising featuring Sarah Jessica Parker, consumer outreach, sampling, retail, ePharmacy, and telehealth launched in July 2026.

• Cash-pay pricing: $79 for 25 vials for one month or $198 for 75 vials for three months ($66/month); no prior authorization required, and HSA/FSA eligible.

• Cash was ~$197M as of Q3 2026.

Market opportunity

• US presbyopia affects 128M people; adults 50+ lose an average 1.5 lines of near vision per six years, with a stated $3B potential market.

• More than 60% of US presbyopes would consider an eye-drop solution; early adopter segments include contact lens wearers, post-LASIK patients, and active-lifestyle consumers.

• A conservative 6% adoption scenario equates to ~8M users and a $3B opportunity, using a 42% refill rate; 75% of study respondents said they would continue VIZZ use, and 81% of those would use it 4–7 days per week.